Millendo Therapeutics Inc (MLND) Stock Price, Quote, News and Overview
NASDAQ:MLND - Nasdaq -
MLND Quote, Performance and Key Statistics
1.06
-0.06 (-5.36%)
The current stock price of MLND is 1.06 null. In the past month the price decreased by -7.02%. In the past year, price decreased by -41.44%.
MLND Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MLND
Company Profile
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Company Info
Millendo Therapeutics Inc
Ann Arbor MICHIGAN 48104 US
CEO: Louis Arcudi
Phone: 17348459000.0
Millendo Therapeutics Inc / MLND FAQ
What is the stock price of Millendo Therapeutics Inc today?
The current stock price of MLND is 1.06 null. The price decreased by -5.36% in the last trading session.
What is the ticker symbol for Millendo Therapeutics Inc stock?
The exchange symbol of Millendo Therapeutics Inc is MLND and it is listed on the Nasdaq exchange.
On which exchange is MLND stock listed?
MLND stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Millendo Therapeutics Inc stock?
0 analysts have analysed MLND and the average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06. Check the Millendo Therapeutics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Millendo Therapeutics Inc worth?
Millendo Therapeutics Inc (MLND) has a market capitalization of 20.19M null. This makes MLND a Nano Cap stock.
What are the support and resistance levels for Millendo Therapeutics Inc (MLND) stock?
Millendo Therapeutics Inc (MLND) has a resistance level at 1.32. Check the full technical report for a detailed analysis of MLND support and resistance levels.
Should I buy Millendo Therapeutics Inc (MLND) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MLND, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MLND, evaluating the profitability, health, valuation and growth aspects
- Millendo Therapeutics Inc (MLND) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Millendo Therapeutics Inc (MLND) Sales and EPS estimates to see what analysts future expectations are.
- Millendo Therapeutics Inc (MLND) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Millendo Therapeutics Inc (MLND) Insider and Institutional Ownership to learn about the owners and their transactions.
- Millendo Therapeutics Inc (MLND) Stock Chart to make your own analysis
- Millendo Therapeutics Inc (MLND) Latest news and press-releases to stay up to date.
Does Millendo Therapeutics Inc (MLND) stock pay dividends?
MLND does not pay a dividend.
What is the Price/Earnings (PE) ratio of Millendo Therapeutics Inc (MLND)?
Millendo Therapeutics Inc (MLND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.73).
MLND Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLND. When comparing the yearly performance of all stocks, MLND is a bad performer in the overall market: 98.82% of all stocks are doing better.
MLND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLND. Both the profitability and financial health of MLND have multiple concerns.
MLND Financial Highlights
Over the last trailing twelve months MLND reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 44.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |